| Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ... The Lancet Neurology 18 (9), 845-856, 2019 | 156 | 2019 |
| Quantitative characterization of CD8+ T cell clustering and spatial heterogeneity in solid tumors C Gong, RA Anders, Q Zhu, JM Taube, B Green, W Cheng, IH Bartelink, ... Frontiers in oncology 8, 649, 2019 | 39 | 2019 |
| Reader reaction to “a robust method for estimating optimal treatment regimes” by Zhang et al.(2012) JMG Taylor, W Cheng, JC Foster Biometrics 71 (1), 267-273, 2015 | 36 | 2015 |
| Informing a risk prediction model for binary outcomes with external coefficient information W Cheng, JMG Taylor, T Gu, SA Tomlins, B Mukherjee Journal of the Royal Statistical Society Series C: Applied Statistics 68 (1 …, 2019 | 30 | 2019 |
| Improving estimation and prediction in linear regression incorporating external information from an established reduced model W Cheng, JMG Taylor, PS Vokonas, SK Park, B Mukherjee Statistics in medicine 37 (9), 1515-1530, 2018 | 26 | 2018 |
| Meta-analysis of job-exposure matrix data from multiple sources W Cheng, B Roberts, B Mukherjee, RL Neitzel Journal of exposure science & environmental epidemiology 28 (3), 259-274, 2018 | 16 | 2018 |
| Synthetic data method to incorporate external information into a current study T Gu, JMG Taylor, W Cheng, B Mukherjee Canadian Journal of Statistics 47 (4), 580-603, 2019 | 15 | 2019 |
| Imputation of missing values in a large job exposure matrix using hierarchical information B Roberts, W Cheng, B Mukherjee, RL Neitzel Journal of exposure science & environmental epidemiology 28 (6), 615-648, 2018 | 10 | 2018 |
| Overall disability response score: an integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis I Chang, L Kappos, G Giovannoni, PA Calabresi, A Sandrock, W Cheng, ... Multiple Sclerosis Journal 28 (14), 2263-2273, 2022 | 6 | 2022 |
| Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies SJ Loomis, R Miller, C Castrillo-Viguera, K Umans, W Cheng, J O'Gorman, ... Neurology 102 (3), e207919, 2024 | 3 | 2024 |
| RENEWED: long-term electrophysiological and clinical outcomes in participants previously enrolled in the opicinumab phase 2 study RENEW (1599) O Aktas, F Ziemssen, T Ziemssen, G Comi, H Butzkueven, G Izquierdo, ... Neurology 94 (15 Supplement), 2020 | 3 | 2020 |
| Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics (P3. 2-072) B Zhu, P Calabresi, G Giovannoni, R Kapoor, R Naismith, HP Hartung, ... Neurology 92 (15 Supplement), 2019 | 3 | 2019 |
| Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, phase 2 trial (AFFINITY part 1) PA Calabresi, G Giovannoni, HP Hartung, RT Naismith, R Fox, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 90-91, 2021 | 2 | 2021 |
| ENVISION: A phase 3b/4 randomized, double‐blind, placebo‐controlled, parallel‐group study to verify the clinical benefit of aducanumab in participants with early Alzheimer’s … J Murphy, P Aisen, F Barkhof, C Castrillo‐Viguera, W Cheng, S Cohen, ... Alzheimer's & Dementia 18, e069428, 2022 | 1 | 2022 |
| Providing meaningful interpretation of a performance outcome measure by co-calibration with a patient-reported outcome: illustration with widely used multiple sclerosis measures A Regnault, J Meunier, A Ciesluk, B Zhu, W Cheng, L Zhu, C Ke, ... QUALITY OF LIFE RESEARCH 29 (SUPPL 1), S2-S2, 2020 | 1 | 2020 |
| RENEWED: Long-Term Electrophysiological and Clinical Outcomes in Participants Previously Enrolled in the Opicinumab Phase 2 Study RENEW O Aktas, F Ziemssen, T Ziemssen, G Comi, H Butzkueven, G Izquierdo, ... NEUROLOGY 94 (15), 2020 | 1 | 2020 |
| Progress in assessing and limiting occupational noise exposures in the United States R Neitzel, B Roberts, S Sayler, W Cheng, B Mukherjee The Journal of the Acoustical Society of America 143 (3_Supplement), 1780-1780, 2018 | 1 | 2018 |
| Providing meaningful interpretation of performance outcome measures by co-calibration with patient-reported outcomes through the Rasch model: illustration with multiple … A Regnault, J Meunier, A Ciesluk, W Cheng, B Zhu Journal of Biopharmaceutical Statistics, 1-21, 2023 | | 2023 |
| ENVISION: Increasing diversity of a large phase 3b/4 confirmatory trial of aducanumab to better understand the efficacy and safety among historically underrepresented … PH Montenigro, W Cheng, J O'Gorman, J Murphy, C Gillis, NN Maserejian, ... Alzheimer's & Dementia 18, e069396, 2022 | | 2022 |
| Authors’ corrigenda/corrections des auteurs on synthetic data method to incorporate external information into a current study T Gu, JMG Taylor, W Cheng, B Mukherjee John Wiley & Sons, Inc., 2022 | | 2022 |
Bhramar MukherjeeProfessor of Biostatistics, University of MichiganVerified email at umich.edu
